PMID- 32982204
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1178-2005 (Electronic)
IS  - 1176-9106 (Print)
IS  - 1176-9106 (Linking)
VI  - 15
DP  - 2020
TI  - First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in 
      Patients with Treatment-Naive Chronic Obstructive Pulmonary Disease.
PG  - 2115-2126
LID - 10.2147/COPD.S268905 [doi]
AB  - BACKGROUND: Comparative effects on physical activity of mono and dual 
      bronchodilators remain unclear in patients with treatment-naive chronic 
      obstructive pulmonary disease (COPD). We sought to compare the changes in 
      physical activity before and after tiotropium and tiotropium/olodaterol treatment 
      in treatment-naive COPD patients. METHODS: A prospective, multicenter, 
      randomized, open-labeled, and parallel interventional study was conducted. Eighty 
      Japanese patients with treatment-naive COPD were randomized to receive either 
      tiotropium or tiotropium/olodaterol treatment for 12 weeks. Spirometry and 
      dyspnea index were assessed, and COPD assessment test (CAT) and the 6-minute walk 
      distance (6MWD) were conducted before and after treatment. Evaluation of physical 
      activity was assessed by a triaxle accelerometer over a 2-week period before and 
      after treatment. RESULTS: There were no differences in the mean age (69.8 vs 70.4 
      years), body mass index (BMI) (22.5 vs 22.6 kg/m(2)) and mean % forced expiratory 
      volume in 1 second (%FEV1) at baseline (61.5 vs 62.6%) between the two groups. 
      Changes in FEV1 (mean+/-standard error, 242.8+/-28.8 mL) and transient dyspnea index 
      (TDI) (2.4+/-0.3 points) before and after tiotropium/olodaterol treatment were 
      greater than with tiotropium treatment (104.1+/-31.9 mL, p<0.01 and 1.5+/-0.3, 
      p=0.02, respectively). Changes in the duration of physical activity with 1.0-1.5 
      metabolic equivalents (METs) estimated in the sedentary position following 
      tiotropium/olodaterol treatment (-38.7+/-14.7 min) tended to be reduced more than 
      with tiotropium treatment (-4.6+/-10.6 min) (p=0.06), although those with >/=2.0 METs 
      numerically increased with both treatments (+10.8+/-7.6 min for 
      tiotropium/olodaterol vs +8.3+/-7.6 min for tiotropium, p=0.82). 
      Tiotropium/olodaterol treatment reduced the duration of physical activity with 
      1.0-1.5 METs (regression coefficient, -43.6 [95% CI -84.1, -3.1], p=0.04) in a 
      multiple regression model adjusted for cofounding factors such as age, FEV1, 
      total CAT scores, 6MWD, and TDI. CONCLUSION: This is the first study to report 
      the impact of dual bronchodilator on physical activity in treatment-naive COPD 
      patients of Japanese with low BMI.
CI  - (c) 2020 Takahashi et al.
FAU - Takahashi, Koichiro
AU  - Takahashi K
AUID- ORCID: 0000-0003-0461-5072
AD  - Division of Hematology, Respiratory Medicine and Oncology, Department of Internal 
      Medicine, Faculty of Medicine, Saga University, Saga, Japan.
FAU - Uchida, Masaru
AU  - Uchida M
AUID- ORCID: 0000-0002-2474-5619
AD  - Division of Internal Medicine, Japan Community Health Care Organization Saga 
      Central Hospital, Saga, Japan.
FAU - Kato, Go
AU  - Kato G
AD  - Division of Respiratory Medicine, Saga Prefectural Medical Center Koseikan, Saga, 
      Japan.
FAU - Takamori, Ayako
AU  - Takamori A
AD  - Clinical Research Center, Saga University Hospital, Faculty of Medicine, Saga 
      University, Saga, Japan.
FAU - Kinoshita, Takashi
AU  - Kinoshita T
AD  - Division of Respirology, Neurology, and Rheumatology, Department of Medicine, 
      Kurume University School of Medicine, Fukuoka, Japan.
FAU - Yoshida, Makoto
AU  - Yoshida M
AD  - Division of Respiratory Medicine, National Hospital Organization Fukuoka 
      Hospital, Fukuoka, Japan.
FAU - Tajiri, Ryo
AU  - Tajiri R
AD  - Clinical Research Center, Saga University Hospital, Faculty of Medicine, Saga 
      University, Saga, Japan.
FAU - Kojima, Keisuke
AU  - Kojima K
AD  - Division of Internal Medicine, Imari Arita Kyouritsu Hospital, Saga, Japan.
FAU - Inoue, Hiroshi
AU  - Inoue H
AD  - Division of Internal Medicine, Karatsu Red Cross Hospital, Saga, Japan.
FAU - Kobayashi, Hiromi
AU  - Kobayashi H
AD  - Division of Respiratory Medicine, National Hospital Organization East Saga 
      Hospital, Saga, Japan.
FAU - Sadamatsu, Hironori
AU  - Sadamatsu H
AD  - Division of Hematology, Respiratory Medicine and Oncology, Department of Internal 
      Medicine, Faculty of Medicine, Saga University, Saga, Japan.
FAU - Tashiro, Hiroki
AU  - Tashiro H
AD  - Division of Hematology, Respiratory Medicine and Oncology, Department of Internal 
      Medicine, Faculty of Medicine, Saga University, Saga, Japan.
FAU - Tanaka, Masahide
AU  - Tanaka M
AD  - Division of Hematology, Respiratory Medicine and Oncology, Department of Internal 
      Medicine, Faculty of Medicine, Saga University, Saga, Japan.
FAU - Hayashi, Shinichiro
AU  - Hayashi S
AUID- ORCID: 0000-0003-4314-8526
AD  - Division of Internal Medicine, Kouhoukai Takagi Hospital, Fukuoka, Japan.
FAU - Kawaguchi, Atsushi
AU  - Kawaguchi A
AD  - Clinical Research Center, Saga University Hospital, Faculty of Medicine, Saga 
      University, Saga, Japan.
AD  - Education and Research Center for Community Medicine, Faculty of Medicine, Saga 
      University, Saga, Japan.
FAU - Kimura, Shinya
AU  - Kimura S
AD  - Division of Hematology, Respiratory Medicine and Oncology, Department of Internal 
      Medicine, Faculty of Medicine, Saga University, Saga, Japan.
FAU - Sueoka-Aragane, Naoko
AU  - Sueoka-Aragane N
AD  - Division of Hematology, Respiratory Medicine and Oncology, Department of Internal 
      Medicine, Faculty of Medicine, Saga University, Saga, Japan.
FAU - Kawayama, Tomotaka
AU  - Kawayama T
AUID- ORCID: 0000-0002-9537-4229
AD  - Division of Respirology, Neurology, and Rheumatology, Department of Medicine, 
      Kurume University School of Medicine, Fukuoka, Japan.
CN  - Saga-naive COPD Physical Activity Evaluation (SCOPE) Study Investigator Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20200914
PL  - New Zealand
TA  - Int J Chron Obstruct Pulmon Dis
JT  - International journal of chronic obstructive pulmonary disease
JID - 101273481
RN  - 0 (Adrenergic beta-2 Receptor Agonists)
RN  - 0 (Benzoxazines)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Drug Combinations)
RN  - VD2YSN1AFD (olodaterol)
RN  - XX112XZP0J (Tiotropium Bromide)
SB  - IM
MH  - *Adrenergic beta-2 Receptor Agonists/therapeutic use
MH  - Aged
MH  - *Benzoxazines/therapeutic use
MH  - Bronchodilator Agents/therapeutic use
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Exercise
MH  - Female
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Lung
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - *Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy
MH  - *Tiotropium Bromide/therapeutic use
MH  - Treatment Outcome
PMC - PMC7501469
OTO - NOTNLM
OT  - chronic obstructive pulmonary disease
OT  - long-acting beta 2 agonist
OT  - long-acting muscarinic antagonist
OT  - physical activity
COIS- This study was financially supported by Nippon Boehringer Ingelheim Co., Ltd. as 
      an independent investigator study. Dr. Koichiro Takahashi received lecture fees 
      from Nippon Boehringer Ingelheim and AstraZeneca. Dr. Takashi Kinoshita received 
      grants from Daiichi Sankyo. Dr. Makoto Yoshida received lecture fees from 
      AstraZeneca, GlaxoSmithKline and Novartis pharma. Dr. Tomotaka Kawayama received 
      grants from Novartis Pharma, and lecture fees from AstraZeneca, GlaxoSmithKline, 
      Boehringer Ingelheim, Novartis Pharma, Teijin Pharma and Home Healthcare, Sanofi, 
      Kyorin Pharmaceutical, and Meiji Seika Pharma. Dr. Masaru Uchida, Dr. Go Kato, 
      Dr. Ayako Takamori, Dr. Makoto Yoshida, Dr. Ryo Tajiri, Dr. Keisuke Kojima, Dr. 
      Hiroshi Inoue, Dr. Hiromi Kobayashi, Dr. Hironori Sadamatsu, Dr. Hiroki Tashiro, 
      Dr. Masahide Tanaka, Dr. Shinichiro Hayashi, Dr. Atsushi Kawaguchi, Dr. Shinya 
      Kimura and Dr. Naoko Sueoka-Aragane did not have any conflicts of interests.
EDAT- 2020/09/29 06:00
MHDA- 2021/06/24 06:00
PMCR- 2020/09/14
CRDT- 2020/09/28 05:37
PHST- 2020/06/26 00:00 [received]
PHST- 2020/08/18 00:00 [accepted]
PHST- 2020/09/28 05:37 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/09/14 00:00 [pmc-release]
AID - 268905 [pii]
AID - 10.2147/COPD.S268905 [doi]
PST - epublish
SO  - Int J Chron Obstruct Pulmon Dis. 2020 Sep 14;15:2115-2126. doi: 
      10.2147/COPD.S268905. eCollection 2020.